 REDWOOD CITY, Calif., Oct. 27, 2020 GLOBE NEWSWIRE -- Allakos Inc. Nasdaq: ALLK Allakos or the Company, a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The preliminary financial results are subject to finalization of the Companys customary quarterly financial close process. 